Total Funding
69
48
Total FundingSeries B raised
Growth Score
-3 pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
18546
SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.
- Axel Mescheder: Chief Medical OfficerPast Role: Lanthio Pharma, Chief Medical and Development Officer
- Raymond Barlow: Chief Executive OfficerPast Role: Kiadis Pharma, Chief Business Officer
About the Company
SynOx Therapeutics focuses on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for diffuse tenosynovial giant cell tumors and other conditions. The company is supported by experienced investors with a history in biopharma development.
